{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:30:38Z","timestamp":1787761838241,"version":"build-2784847793"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05722-1","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:01:53Z","timestamp":1727067713000},"page":"2711-2725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biological therapy for psoriatic arthritis: current state and future perspectives"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6136-5770","authenticated-orcid":false,"given":"Dominika","family":"Boboryko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0244-3526","authenticated-orcid":false,"given":"Joanna","family":"Olejnik-Wojciechowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0676-7403","authenticated-orcid":false,"given":"Magdalena","family":"Baranowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5288-1577","authenticated-orcid":false,"given":"Aleksandra Wiktoria","family":"Bratborska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6080-6104","authenticated-orcid":false,"given":"Patryk","family":"Sk\u00f3rka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-1208","authenticated-orcid":false,"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"7","key":"5722_CR1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","volume":"142","author":"PC van de Kerkhof","year":"2022","unstructured":"van de Kerkhof PC (2022) From empirical to pathogenesis-based treatments for Psoriasis. J Invest Dermatol 142(7):1778\u20131785","journal-title":"J Invest Dermatol"},{"issue":"5","key":"5722_CR2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J, Psoriasis (2009) N Engl J Med 361(5):496\u2013509","journal-title":"N Engl J Med"},{"key":"5722_CR3","doi-asserted-by":"crossref","unstructured":"Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, Gisondi P, Balint PV, Bertheussen H, Boehncke WH, Damjanov NS, De Wit M, Errichetti E, Marzo-Ortega H, Protopopov M, Puig L, Queiro R, Ruscitti P, Savage L, Schett G, Siebert S, Stamm TA, Studenic P, Tinazzi I, Van Den Bosch FE, Mil A, Watad A, Smolen JS, McGonagle DG (2023) EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. ard-2023-224148.","DOI":"10.1136\/ard-2023-224148"},{"issue":"12","key":"5722_CR4","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1007\/s10067-020-05132-1","volume":"39","author":"YJ Su","year":"2020","unstructured":"Su YJ (2020) Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing. Clin Rheumatol 39(12):3677\u20133684","journal-title":"Clin Rheumatol"},{"issue":"8","key":"5722_CR5","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673","journal-title":"Arthritis Rheum"},{"key":"5722_CR6","unstructured":"Tiwari V, Brent LH, Psoriatic A (2024) Jan 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. PMID: 31613490"},{"issue":"1","key":"5722_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55\u201378","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"5722_CR8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3899\/jrheum.130453","volume":"40","author":"V Chandran","year":"2013","unstructured":"Chandran V, Gladman DD, Helliwell PS, Gudbj\u00f6rnsson B (2013) Arthritis mutilans: a report from the GRAPPA 2012 Annual Meeting. J Rheumatol 40(8):1419\u20131422","journal-title":"J Rheumatol"},{"issue":"3","key":"5722_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C (2019) Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol 15(3):153\u2013166","journal-title":"Nat Rev Rheumatol"},{"key":"5722_CR10","doi-asserted-by":"crossref","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Ca\u00f1ete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis ard-2024-225531","DOI":"10.1136\/ard-2024-225531"},{"issue":"3","key":"5722_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/25785826.2023.2172808","volume":"46","author":"K Yamaoka","year":"2023","unstructured":"Yamaoka K, Oku K (2023) JAK inhibitors in rheumatology. Immunol Med 46(3):143\u2013152","journal-title":"Immunol Med"},{"key":"5722_CR12","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/CCID.S433367","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L (2023) JAK inhibitors in Psoriatic Disease. Clin Cosmet Investig Dermatol 16:3129\u20133145","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"5722_CR13","first-page":"19","volume":"20","author":"B Klein","year":"2022","unstructured":"Klein B, Treudler R, Simon JC (2022) JAK-inhibitors in dermatology \u2013 small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. JDDG J Dtsch Dermatol Ges 20(1):19\u201324","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"5722_CR14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","volume":"10","author":"S D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti MS, Delle Sedie A, Foti R, Gerli R, Lomater C, Lubrano E, Marchesoni A, Zabotti A, Salvarani C, Scrivo R, Scarpa R, Tramontano G, Nannini C, Lorenzin M, Fabbroni M, Martinis F, Perricone R, Carli L, Visalli E, Rovera G, Perrotta FM, Quartuccio L, Altobelli A, Costa L, Niccoli L, Ortolan A, Caso F (2019) Effectiveness of Adalimumab for the treatment of psoriatic arthritis: an Italian real-life Retrospective Study. Front Pharmacol 10:1497","journal-title":"Front Pharmacol"},{"issue":"7","key":"5722_CR15","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.3390\/ijms24076384","volume":"24","author":"S Sundanum","year":"2023","unstructured":"Sundanum S, Orr C, Veale D (2023) Targeted therapies in Psoriatic Arthritis\u2014An update. Int J Mol Sci 24(7):6384","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5722_CR16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/BOR.0000000000000232","volume":"28","author":"A Paine","year":"2016","unstructured":"Paine A, Ritchlin C (2016) Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol 28(1):66","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"5722_CR17","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, Sharp JT, Ory PA, Perdok RJ, Weinberg MA (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279\u20133289","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5722_CR18","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264\u20132272","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5722_CR19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227\u20131236","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5722_CR20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976\u2013986","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5722_CR21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48\u201355","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5722_CR22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordstr\u00f6m D (2017) Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum 46(6):732\u2013739","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5722_CR23","first-page":"93","volume":"1","author":"GA Vena","year":"2007","unstructured":"Vena GA, Cassano N (2007) Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biol Targets Ther 1(2):93\u2013103","journal-title":"Biol Targets Ther"},{"issue":"2","key":"5722_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","volume":"66","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J (2007) Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 66(2):163\u2013168","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5722_CR25","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3899\/jrheum.100069","volume":"37","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Sampalis JS, Illouz O, Gu\u00e9rette B (2010) Responses to Adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 37(9):1898\u20131906","journal-title":"J Rheumatol"},{"issue":"4","key":"5722_CR26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis 72(4):517\u2013524","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5722_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14397595.2019.1589739","volume":"30","author":"A Morita","year":"2020","unstructured":"Morita A, Okuyama R, Katoh N, Tateishi C, Masuda K, Komori T, Ogawa E, Makino T, Nishida E, Nishimoto S, Muramoto K, Tsuruta D, Ihn H (2020) Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): a prospective, observational study. Mod Rheumatol 30(1):155\u2013165","journal-title":"Mod Rheumatol"},{"issue":"9227","key":"5722_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet Lond Engl 356(9227):385\u2013390","journal-title":"Lancet Lond Engl"},{"key":"5722_CR29","unstructured":"Pan A, Gerriets VE (2023) Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. PMID: 31424836"},{"key":"5722_CR30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Ueda N (2018) Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 comparison among therapeutic TNF-\u03b1 antagonists. Cytokine 101:56\u201363","journal-title":"Cytokine"},{"key":"5722_CR31","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","volume":"340","author":"W Sterry","year":"2010","unstructured":"Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147","journal-title":"BMJ"},{"issue":"7","key":"5722_CR32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB (2019) Etanercept and Methotrexate as Monotherapy or in combination for psoriatic arthritis: primary results from a Randomized, Controlled Phase III Trial. Arthritis Rheumatol 71(7):1112\u20131124","journal-title":"Arthritis Rheumatol"},{"key":"5722_CR33","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for Active Crohn\u2019s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. ;121(5)","DOI":"10.1053\/gast.2001.28674"},{"issue":"4","key":"5722_CR34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","volume":"121","author":"CS Foster","year":"2003","unstructured":"Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Vredeveld CM (2003) Efficacy of Etanercept in preventing relapse of Uveitis controlled by Methotrexate. Arch Ophthalmol 121(4):437\u2013440","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"5722_CR35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498\u2013505","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5722_CR36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF03325638","volume":"27","author":"M Papoutsaki","year":"2013","unstructured":"Papoutsaki M, Os\u00f3rio F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A (2013) Infliximab in Psoriasis and Psoriatic Arthritis. BioDrugs 27(1):13\u201323","journal-title":"BioDrugs"},{"issue":"8","key":"5722_CR37","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) IMPACT 2 Trial investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150\u20131157","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5722_CR38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayov\u00e1 H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541\u2013548","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5722_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10067-021-05874-6","volume":"41","author":"MS Chimenti","year":"2022","unstructured":"Chimenti MS, Conigliaro P, Caso F, Costa L, Ortolan A, Triggianese P, Tasso M, Fonti GL, Lorenzin MG, Perricone R, Ramonda R (2022) Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. Clin Rheumatol 41(1):75\u201384","journal-title":"Clin Rheumatol"},{"issue":"8","key":"5722_CR40","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, G\u00f3mez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64(8):2504\u20132517","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5722_CR41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, Van Der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A (2014) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73(9):1689\u20131694","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5722_CR42","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and Efficacy of Intravenous Golimumab in patients with active psoriatic arthritis. Arthritis Rheumatol 69(11):2151\u20132161","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5722_CR43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","volume":"79","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos FM, Gomes JL, Aguiar R, Pinto P, Videira T, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ribeiro P\u00c1, Martins FM, Canh\u00e3o H, McInnes IB, Ribeiro RM, Fonseca JE (2020) GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis 79(4):490\u2013498","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5722_CR44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","volume":"13","author":"A Nesbitt","year":"2007","unstructured":"Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13(11):1323\u20131332","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"5722_CR45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/1744666X.2020.1713754","volume":"16","author":"M Esposito","year":"2020","unstructured":"Esposito M, Carubbi F, Giunta A, Alunno A, Giacomelli R, Fargnoli MC (2020) Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Rev Clin Immunol 16(2):119\u2013128 Epub 2020 Jan 22. PMID: 31917928","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"5722_CR46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/1744666X.2015.1009897","volume":"11","author":"R Baronaite Hansen","year":"2015","unstructured":"Baronaite Hansen R, Kavanaugh A (2015) Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 11(3):307\u2013318","journal-title":"Expert Rev Clin Immunol"},{"key":"5722_CR47","doi-asserted-by":"publisher","unstructured":"Deeks ED (2016) Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. BioDrugs. 30(6):607\u2013617. https:\/\/doi.org\/10.1007\/s40259-016-0197-y. PMID: 27704400","DOI":"10.1007\/s40259-016-0197-y"},{"issue":"1","key":"5722_CR48","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","volume":"1","author":"P Mease","year":"2015","unstructured":"Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczy\u0144ski P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landew\u00e9 R, de Longueville M, Hoepken B, Peterson L, van der Heijde D (2015) Effect of certolizumab pegol over 96\u2005weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 1(1):e000119","journal-title":"RMD Open"},{"issue":"12","key":"5722_CR49","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","volume":"37","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2018) Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized co ntrolled trial. Clin Rheumatol 37(12):3285\u20133296","journal-title":"Clin Rheumatol"},{"issue":"7","key":"5722_CR50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/09546634.2019.1605143","volume":"31","author":"F Carubbi","year":"2020","unstructured":"Carubbi F, Fidanza R, Palmieri M, Ventura A, Tambone S, Cipriani P, Giacomelli R, Fargnoli MC (2020) Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. J Dermatol Treat 31(7):692\u2013697","journal-title":"J Dermatol Treat"},{"key":"5722_CR51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-065X.2008.00699.x","volume":"226","author":"Y Iwakura","year":"2008","unstructured":"Iwakura Y, Nakae S, Saijo S, Ishigame H (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226:57\u201379","journal-title":"Immunol Rev"},{"issue":"9","key":"5722_CR52","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361(9):888\u2013898","journal-title":"N Engl J Med"},{"issue":"5 Suppl 93","key":"5722_CR53","first-page":"S115","volume":"33","author":"HJ Johnsson","year":"2015","unstructured":"Johnsson HJ, McInnes IB (2015) Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clin Exp Rheumatol 33(5 Suppl 93):S115\u2013118","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5722_CR54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","volume":"82","author":"C Webers","year":"2023","unstructured":"Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landew\u00e9 RBM, Ramiro S, van der Heijde D, Nikiphorou E (2023) Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 82(1):130\u2013141","journal-title":"Ann Rheum Dis"},{"issue":"9625","key":"5722_CR55","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665\u20131674","journal-title":"Lancet"},{"issue":"9625","key":"5722_CR56","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675\u20131684","journal-title":"Lancet"},{"issue":"9894","key":"5722_CR57","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780\u2013789","journal-title":"Lancet"},{"issue":"6","key":"5722_CR58","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, Group on behalf of the P 2 S (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999","journal-title":"Ann Rheum Dis"},{"key":"5722_CR59","unstructured":"Clinical Review Report (2018 Mar) Indication: for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet]. Guselkumab (Tremfya): (Janssen Inc. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON), p 30480924"},{"issue":"10230","key":"5722_CR60","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230):1115\u20131125","journal-title":"Lancet"},{"issue":"10230","key":"5722_CR61","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230):1126\u20131136","journal-title":"Lancet"},{"issue":"1","key":"5722_CR62","doi-asserted-by":"crossref","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, Chakravarty SD, Zazzetti F, Subramanian RA, Xu XL, Zuraw QC, Sheng S, Jiang Y, Agarwal P, Zhou B, Zhuang Y, Shawi M, Karyekar CS, Deodhar A (2021) Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open 7(1):e001457","journal-title":"RMD Open"},{"issue":"4","key":"5722_CR63","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD, Xu XL, Subramanian RA, Agarwal P, Sheng S, Jiang Y, Zhou B, Zhuang Y, van der Heijde D, Mease PJ (2021) Efficacy and safety of Guselkumab, an Interleukin-23p19\u2013Specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol 73(4):604\u2013616","journal-title":"Arthritis Rheumatol"},{"key":"5722_CR64","doi-asserted-by":"publisher","unstructured":"McKeage K, Duggan S, Risankizumab (2019) First Global Approval. Drugs. 79(8):893\u2013900. https:\/\/doi.org\/10.1007\/s40265-019-01136-7. PMID: 31098898","DOI":"10.1007\/s40265-019-01136-7"},{"issue":"5","key":"5722_CR65","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","volume":"9","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Kellner H, Morita A, Kivitz AJ, Aslanyan S, Padula SJ, Topp AS, Eldred A, Behrens F, Papp KA (2022) Long-term efficacy and safety of Risankizumab in patients with active psoriatic arthritis: results from a 76-Week phase 2 Randomized Trial. Rheumatol Ther 9(5):1361\u20131375","journal-title":"Rheumatol Ther"},{"issue":"2","key":"5722_CR66","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Behrens F (2022) Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 81(2):225\u2013231","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5722_CR67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Alperovich G, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Kivitz A (2022) Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis 81(3):351\u2013358","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5722_CR68","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","volume":"62","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Soliman AM, Eldred A, Barcomb L, Behrens F (2023) Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatol Oxf Engl 62(6):2113\u20132121","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"5722_CR69","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","volume":"62","author":"A \u00d6st\u00f6r","year":"2023","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Lu W, Wang Z, Soliman AM, Eldred A, Padilla B, Kivitz A (2023) Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatol Oxf Engl 62(6):2122\u20132129","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"5722_CR70","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/rheumatology\/keac342","volume":"62","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, Eldred A, Behrens F (2023) Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatol Oxf Engl 62(2):629\u2013637","journal-title":"Rheumatol Oxf Engl"},{"issue":"9","key":"5722_CR71","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3390\/genes13091643","volume":"13","author":"EV Meehan","year":"2022","unstructured":"Meehan EV, Wang K (2022) Interleukin-17 family cytokines in metabolic disorders and Cancer. Genes 13(9):1643","journal-title":"Genes"},{"issue":"3","key":"5722_CR72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 55(3):379","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"5722_CR73","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","volume":"6","author":"H Park","year":"2005","unstructured":"Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6(11):1133\u20131141","journal-title":"Nat Immunol"},{"key":"5722_CR74","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fmed.2018.00364","volume":"5","author":"M Robert","year":"2019","unstructured":"Robert M, Miossec P (2019) IL-17 in rheumatoid arthritis and Precision Medicine: from Synovitis expression to circulating bioactive levels. Front Med 5:364","journal-title":"Front Med"},{"key":"5722_CR75","doi-asserted-by":"crossref","unstructured":"Kivitz AJ, Kremer JM, Legerton CW, Pricop L, Singhal A (2024) Efficacy and safety of Secukinumab in US patients with psoriatic arthritis: a subgroup analysis of the phase 3 FUTURE studies. Rheumatol Ther","DOI":"10.1007\/s40744-024-00666-1"},{"key":"5722_CR76","doi-asserted-by":"crossref","first-page":"1294247","DOI":"10.3389\/fmed.2023.1294247","volume":"10","author":"JJ Alegre-Sancho","year":"2023","unstructured":"Alegre-Sancho JJ, N\u00fa\u00f1ez-Monje V, Campos-Fern\u00e1ndez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M, Garijo-Bufort M, Pedraz-Penalva T, Pe\u00f1a-Gonz\u00e1lez C, de la Morena I, Bedoya-Sanch\u00eds D, Yankova-Komsalova L, Conesa-Mateos A, Martinez-Crist\u00f3bal A, Navarro-Blasco FJ, Senabre-Gallego JM, Sivera F (2023) Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Front Med 10:1294247","journal-title":"Front Med"},{"issue":"14","key":"5722_CR77","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landew\u00e9 R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab Inhibition of Interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373(14):1329\u20131339","journal-title":"N Engl J Med"},{"issue":"3","key":"5722_CR78","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(21)00354-4","volume":"4","author":"V Strand","year":"2022","unstructured":"Strand V, Kaeley GS, Bergman MJ, Gladman DD, Coates LC, Sherif B, Hur P, Parikh B, Gilloteau I, Mease PJ (2022) The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Lancet Rheumatol 4(3):e208\u2013e219","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"5722_CR79","doi-asserted-by":"crossref","first-page":"e001600","DOI":"10.1136\/rmdopen-2021-001600","volume":"7","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Landew\u00e9 R, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Readie A, Mpofu S, Delicha EM, Pricop L, van der Heijde D (2021) Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open 7(2):e001600","journal-title":"RMD Open"},{"key":"5722_CR80","doi-asserted-by":"publisher","unstructured":"Syed YY, Ixekizumab (2017) A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 18(1):147\u2013158. https:\/\/doi.org\/10.1007\/s40257-017-0254-4. PMID: 28138946","DOI":"10.1007\/s40257-017-0254-4"},{"key":"5722_CR81","doi-asserted-by":"crossref","unstructured":"Takami K, Tsuji S, Sato S, Akaji K, Yamashita C, Hiroumi S, Konaka H, Hayashi M, Higashiyama M (2023) Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis. Mod Rheumatol. road111","DOI":"10.1093\/mr\/road111"},{"key":"5722_CR82","doi-asserted-by":"crossref","unstructured":"Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB (2024) Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther","DOI":"10.1007\/s40744-024-00652-7"},{"key":"5722_CR83","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","volume":"21","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, Orbai AM, Klitz U, Wei JCC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H (2019) Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther 21:38","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"5722_CR84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jdv.15921","volume":"34","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C (2020) Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol 34(2):301\u2013309","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"5722_CR85","doi-asserted-by":"crossref","first-page":"e13403","DOI":"10.1111\/dth.13403","volume":"33","author":"P Facheris","year":"2020","unstructured":"Facheris P, Valenti M, Pavia G, Guanziroli E, Narcisi A, Borroni RG, Costanzo A (2020) Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther 33(3):e13403","journal-title":"Dermatol Ther"},{"issue":"1","key":"5722_CR86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignahi F, Thyssen JP, Burge R, Mallbris L (2020) Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol JEADV 34(1):39\u201346","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"5722_CR87","doi-asserted-by":"crossref","first-page":"2340107","DOI":"10.1080\/09546634.2024.2340107","volume":"35","author":"L Schaeffer","year":"2024","unstructured":"Schaeffer L, Ben-Anaya N, Sorbe C, Rustenbach SJ, Mrowietz U, Augustin M (2024) Real-world outcomes and drug survival of brodalumab: results from the German psoriasis Registry PsoBest. J Dermatol Treat 35(1):2340107","journal-title":"J Dermatol Treat"},{"issue":"6","key":"5722_CR88","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","volume":"33","author":"M Kojanova","year":"2022","unstructured":"Kojanova M, Hugo J, Velackova B, Cetkovska P, Fialova J, Dolezal T, Tichy M, Gkalpakiotis S, BIOREP study group (2022) Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatol Treat 33(6):2827\u20132837","journal-title":"J Dermatol Treat"},{"issue":"2","key":"5722_CR89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Hjuler KF, Raymond K, McInnes I (2021) Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis 80(2):185\u2013193","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5722_CR90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40268-023-00422-w","volume":"23","author":"CDB Elgaard","year":"2023","unstructured":"Elgaard CDB, Iversen L, Hjuler KF (2023) Single-centre real-world study on drug survival and effectiveness of Brodalumab for treatment of Psoriasis and Psoriatic Arthritis. Drugs RD 23(2):155\u2013163","journal-title":"Drugs RD"},{"issue":"2","key":"5722_CR91","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2023.2277266","volume":"20","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Shaw S (2024) Bimekizumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 20(2):155\u2013168","journal-title":"Expert Rev Clin Immunol"},{"issue":"10370","key":"5722_CR92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, Landew\u00e9 R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ (2023) Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 401(10370):25\u201337","journal-title":"Lancet"},{"issue":"1","key":"5722_CR93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/jcm12010035","volume":"12","author":"G Kokolakis","year":"2022","unstructured":"Kokolakis G, Ghoreschi K (2022) The clinical significance of simultaneous IL-17A and IL-17F blockade in Psoriasis Non-responding to Anti-IL17A Therapy. J Clin Med 12(1):35","journal-title":"J Clin Med"},{"issue":"9","key":"5722_CR94","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/imt-2018-0014","volume":"10","author":"G Zizzo","year":"2018","unstructured":"Zizzo G, Gremese E, Ferraccioli G (2018) Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. Immunotherapy 10(9):807\u2013821","journal-title":"Immunotherapy"},{"issue":"9","key":"5722_CR95","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550\u20131558","journal-title":"Ann Rheum Dis"},{"key":"5722_CR96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PTT.S146076","volume":"8","author":"A Noisette","year":"2018","unstructured":"Noisette A, Hochberg MC (2018) Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. Psoriasis Targets Ther 8:31\u201339","journal-title":"Psoriasis Targets Ther"},{"issue":"4","key":"5722_CR97","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63(4):939\u2013948","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5722_CR98","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1093\/rheumatology\/keac073","volume":"61","author":"M \u00d8stergaard","year":"2022","unstructured":"\u00d8stergaard M, Bird P, Pachai C, Du S, Wu C, Landis J, Fuerst T, Ahmad HA, Connolly SE, Conaghan PG (2022) Implementation of the OMERACT psoriatic arthritis magnetic resonance imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatol Oxf Engl 61(11):4305\u20134313","journal-title":"Rheumatol Oxf Engl"},{"key":"5722_CR99","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen ML, Nymand L, Kristensen LE, Thyssen JP, Thomsen SF, Cordtz RL, Loft N, Skov L, Bryld LE, Rasmussen MK, H\u00f8jgaard P, Kristensen S, Dreyer L (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 53:151979","journal-title":"Semin Arthritis Rheum"},{"key":"5722_CR100","first-page":"1759720X2092920","volume":"12","author":"WC Chao","year":"2020","unstructured":"Chao WC, Wang CY, Hsu BC, Lin CH, Huang WN, Chen YH, Wu CL, Chen HH (2020) Factors associated with sepsis risk in immune-mediated inflammatory diseases receiving tumor necrosis factor inhibitors: a nationwide study. Ther Adv Musculoskelet Dis 12:1759720X20929208","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"5722_CR101","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3390\/microorganisms11092231","volume":"11","author":"S Kamath","year":"2023","unstructured":"Kamath S, Hammad Altaq H, Abdo T (2023) Management of Sepsis and septic shock: what have we learned in the last two. Decades? Microorganisms 11(9):2231","journal-title":"Decades? Microorganisms"},{"issue":"3","key":"5722_CR102","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10067-023-06834-y","volume":"43","author":"N Hijazi","year":"2024","unstructured":"Hijazi N, Gazitt T, Haddad A, Elias M, Kassem S, Feldhamer I, Cohen AD, Sar S, Tomkins-Netzer O, Saliba W, Zisman D (2024) The risk factors for uveitis among psoriatic arthritis patients: a population-based cohort study. Clin Rheumatol 43(3):1053\u20131061","journal-title":"Clin Rheumatol"},{"key":"5722_CR103","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","volume":"3","author":"CT Ritchlin","year":"2019","unstructured":"Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, Srivastava B, Langholff W, Gottlieb AB (2019) Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatol 3:52","journal-title":"BMC Rheumatol"},{"issue":"1","key":"5722_CR104","doi-asserted-by":"crossref","first-page":"158","DOI":"10.55563\/clinexprheumatol\/3qiqk3","volume":"39","author":"A Ortolan","year":"2021","unstructured":"Ortolan A, Ramonda R, Lorenzin M, Pesavento R, Spinazz\u00e8 A, Felicetti M, Nardin C, Rattazzi M, Doria A, Puato M (2021) Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. Clin Exp Rheumatol 39(1):158\u2013161","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"5722_CR105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.phrs.2008.02.006","volume":"57","author":"R Saraceno","year":"2008","unstructured":"Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S (2008) Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 57(4):290\u2013295","journal-title":"Pharmacol Res"},{"issue":"3","key":"5722_CR106","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","volume":"71","author":"P Mease","year":"2019","unstructured":"Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P (2019) Safety of Ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res 71(3):367\u2013378","journal-title":"Arthritis Care Res"},{"issue":"7","key":"5722_CR107","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/pharmaceutics15071933","volume":"15","author":"F Calapai","year":"2023","unstructured":"Calapai F, Ammendolia I, Cardia L, Curr\u00f2 M, Calapai G, Esposito E, Mannucci C (2023) Pharmacovigilance of Risankizumab in the treatment of Psoriasis and arthritic psoriasis: real-World Data from EudraVigilance Database. Pharmaceutics 15(7):1933. https:\/\/doi.org\/10.3390\/pharmaceutics15071933","journal-title":"Pharmaceutics"},{"issue":"4","key":"5722_CR108","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljad186","volume":"189","author":"S Gerdes","year":"2023","unstructured":"Gerdes S, Staubach P, Dirschka T, Wetzel D, Weirich O, Niesmann J, Da Mota R, Rothhaar A, Ardabili M, Vlasitz G, Feldwisch J, Osterling Koskinen L, Ohlman S, Peloso PM, Brun NC, Frejd FY (2023) Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. Br J Dermatol 189(4):381\u2013391","journal-title":"Br J Dermatol"},{"key":"5722_CR109","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00132-014-2321-3","volume":"43","author":"S Rehart","year":"2014","unstructured":"Rehart S, Henniger M (2014) Rolle Des Orthop\u00e4den Bei Der Therapie rheumatischer Erkrankungen Mit Biologika. Orthop\u00e4de 43:585\u2013595. https:\/\/doi.org\/10.1007\/s00132-014-2321-3","journal-title":"Orthop\u00e4de"},{"key":"5722_CR110","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11926-015-0517-0","volume":"17","author":"LC Coates","year":"2015","unstructured":"Coates LC, Helliwell PS (2015) Treat to target in psoriatic Arthritis\u2014Evidence, Target, Research Agenda. Curr Rheumatol Rep 17:41. https:\/\/doi.org\/10.1007\/s11926-015-0517-0","journal-title":"Curr Rheumatol Rep"},{"key":"5722_CR111","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s10067-024-06867-x","volume":"43","author":"IA Al-Homood","year":"2024","unstructured":"Al-Homood IA, Al Ghanim N, Fatani MIA et al (2024) The Saudi consensus recommendations for the management of psoriatic arthritis (2023). Clin Rheumatol 43:879\u2013894. https:\/\/doi.org\/10.1007\/s10067-024-06867-x","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5722_CR112","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y (2020) Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and their impact on comorbidities: a Literature Review. Int J Mol Sci 21(5):1690","journal-title":"Int J Mol Sci"},{"key":"5722_CR113","doi-asserted-by":"publisher","unstructured":"Freire M, Rodr\u00edguez J, M\u00f6ller I, Valc\u00e1rcel A, Tornero C, D\u00edaz G, Armend\u00e1riz Y, Paredes S (2011) Jan-Feb;7(1):20\u2009\u2013\u20096 Prevalencia de s\u00edntomas de ansiedad y de depresi\u00f3n en pacientes con artritis psori\u00e1sica en consultas de reumatolog\u00eda [Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics]. Reumatol Clin. Spanish. https:\/\/doi.org\/10.1016\/j.reuma.2010.03.003. Epub 2010 Jun 15. Erratum in: Reumatol Clin. 2011 Jul-Aug;7(4):274-5. PMID: 21794775","DOI":"10.1016\/j.reuma.2010.03.003"},{"key":"5722_CR114","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1007\/s10067-022-06300-1","volume":"41","author":"SA Tabra","year":"2022","unstructured":"Tabra SA, abd Elghany SE, Amer RA et al (2022) Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol 41:3391\u20133399. https:\/\/doi.org\/10.1007\/s10067-022-06300-1","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05722-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:05:28Z","timestamp":1733310328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":114,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5722"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05722-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that no part of this narrative review is copied or published elsewhere, in whole or in part, in any language.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}